BPG is committed to discovery and dissemination of knowledge
Home / Archive / Volume 14, Issue 4
  • This Article
Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
  • Total Article Views (0)
All Articles published online
The chart showing PDF series, HTML series, Figures (1-4) series, Tables (1-2) series.
Item 
Count 
PDF4
HTML19
Figures (1-4)0
Tables (1-2)0
 Sum=23
Featured Article
The chart showing Browse series, Download series.
Item 
Count 
Browse13
Download40
 Sum=53
Publishing Process of This Article
The chart showing Browse series, Download series.
Item 
Count 
Browse3
Download3
 Sum=6
Dec 25, 2025 (publication date) through Dec 23, 2025
Times Cited of This Article
  • Times Cited  (0)
Journal Information of This Article
Publication Name
World Journal of Nephrology
ISSN
2220-6124
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews
Copyright ©The Author(s) 2025.
World J Nephrol. Dec 25, 2025; 14(4): 109099
Published online Dec 25, 2025. doi: 10.5527/wjn.v14.i4.109099
Figure 1
Open in New Tab Full Size Figure Download Figure
Figure 1 shows various clinical utilities of donor-derived cell-free DNA. dd-cfDNA: Donor-derived cell-free DNA; ABMR: Antibody-mediated rejection.
Figure 2
Open in New Tab Full Size Figure Download Figure
Figure 2 Shows various confounding conditions that may lead to elevated donor-derived cell-free DNA levels or interfere with the assay, independent of rejection. dd-cfDNA: Donor-derived cell-free DNA; IFTA: Interstitial fibrosis and tubular atrophy; DGF: Delayed graft function.
Figure 3
Open in New Tab Full Size Figure Download Figure
Figure 3 Potential future aims for ongoing studies. ABMR: Antibody-mediated rejection; TCMR: T cell-mediated rejection; AKI: Acute kidney injury; CKI: Chronic kidney injury; cfDNA: Cell-free DNA.
Figure 4
Open in New Tab Full Size Figure Download Figure
Figure 4 An integrated approach to using donor-derived cell-free DNA for the diagnosis of rejection and renal allograft surveillance. dd-cfDNA: Donor-derived cell-free DNA.
Write to the Help Desk
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

California Corporate Number: 3537345